報價延遲最少15分鐘:2024/05/10 10:31 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.755 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.49/-1.25
|
|
企業價值
59.48M
|
| 資產負債 |
|
每股賬面淨值
0.02
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/10 10:31 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positivecancer cells. |